Stock comparison
Geron
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GERN
Geron
Market cap
$821.15M
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GERN | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 72B | LLY |
| Benjamin Graham | 63D | 86A | LLY |
| Philip Fisher | 52C | 86A | LLY |
| Peter Lynch | 20F | 74B | LLY |
| Joel Greenblatt | 2F | 78C | LLY |
| Charlie Munger | 43D | 85A | LLY |
| Terry Smith | 48D | 77C | LLY |
Side-by-side metrics
| Metric | GERN | LLY |
|---|---|---|
| Market cap | $821.15M | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | - | 34.1x |
| ROIC (TTM) | -7.77% | 32.06% |
| Gross margin | 86.59% | 83.51% |
| Net margin | -35.48% | 34.98% |
| Revenue CAGR 5y | 2.39% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 1.1x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GERN leads on
- EV/EBIT-vs 34.1x+153%
- P/E (TTM)-vs 36.6x+132%
- Revenue CAGR 5y2.39%vs 23.17%+90%
- Debt / Equity1.1xvs 1.4x+21%
LLY leads on
- Net margin34.98%vs -35.48%+199%
- ROIC (TTM)32.06%vs -7.77%+124%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $821.15M+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.